Gilead Moves Into Microbiome In Deal With Second Genome

Gilead lands on Second Genome as its first partner to apply microbiome analysis to pipeline assets to look for biomarkers. Companies also team up on GI drug discovery.

Biofilm - Microbiome - Abstract 3D Illustration
Second Genome will apply its microbiome screening technology to existing Gilead pipeline assets

Gilead Sciences Inc. has been looking for a way into microbiome research for a while, and following a competitive process, settled on a four-year collaboration with Second Genome Inc. to identify biomarkers of clinical response in inflammation, fibrosis and other therapeutic areas. Additionally, the companies will partner to discover new targets and drug candidates for inflammatory bowel disease (IBD) indications.

Gilead selected Second Genome after assessing the technological capabilities of several microbiome-focused biotechs, Gilead senior vice president of research external...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.